On July 13, 2021 Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), reported that its CEO, Anker Lundemose, will be presenting at the 5th annual EU Investor Tour hosted by Solebury Trout, Venrock, and Oppenheimer on 13-14 July (Press release, Mission Therapeutics, JUL 13, 2021, View Source [SID1234584805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Anker will discuss the Company’s business strategy, technology, discovery platform and development programmes in a presentation to investors on Wednesday, 14 July at 10.15am ET / 3.15pm BST. The 30-minute presentation will be followed by a Q&A.

For individuals interested in attending the meeting, please contact the organisers for more information.